Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alaric DeArment

Reporter

Alaric has covered health care and the biopharma industry for over 12 years. He started out covering retail pharmacy for Drug Store News and shifted to writing for the pharma audience at BioPharm Insight, where highlights of his coverage included breaking stories about the early growing pains of CAR-T cell therapy development. Most recently he covered the biopharma beat at MedCity News. His professional interests include cell and gene therapies, hematology-oncology and the intersection of biopharma with artificial intelligence and machine learning. A native of Seattle, he holds a bachelor degree in journalism from Ball State University and also lived in China for three years. He is currently based in Brooklyn. Outside of work, Alaric’s interests include reading, coin collecting, travel and languages.

Latest From Alaric DeArment

Keytruda Expands Cervical Cancer Position With ESMO Data

In addition to securing a key position in first-line disease, Keytruda has potential to expand its presence in later lines with combination data from Seagen/Genmab’s Tivdak.

Biologics ImmunoOncology

AstraZeneca Finds Two More Potential Partners For Imfinzi

Adding oleclumab and monalizumab to the PD-L1 inhibitor improved PFS, while another study showed improved real-world outcomes.

Cancer Biologics

Gilead Builds Up Trodelvy Data In TNBC Ahead Of Competition

Phase III sub-analyses presented at ESMO show the drug providing a survival benefit in a complex subpopulation, as well as improvements to quality of life.

Cancer Biologics

Gene Therapy Situation Gets More Awkward With Another Death In Astellas XLMTM Study

An expert pointed out that XLMTM patients are already at high risk, but if linked to therapy toxicity, the death could doom the ASPIRO trial.

Gene Therapy Biologics

AbbVie Extends Reach Of Regenxbio’s Wet AMD Program

The partnership worth up to $1.75bn removes the significant risk of going it alone in a competitive market as Regenxbio awaits late-stage data for its gene therapy.

Deals Gene Therapy

Mammoth Biosciences Thinks Ultra-Small As It Attains Elephant-Sized Valuation

The Jennifer Doudna-backed startup got a billion-dollar valuation with VC rounds totaling $195m. CEO Trevor Martin talked with Scrip about Mammoth’s ultra-small CRISPR system technology.

Financing Gene Therapy
See All
UsernamePublicRestriction

Register